Skip to content
info@ibsgranada.es
FacebookTwitterLinkedInInstagramYouTube
ibs logo.GRANADA
  • ibs.GRANADA
  • The Institute
    • The Institute
    • Organizational structure
    • Management Units
    • Economic information
    • Centers
    • Responsible Research and Innovation (RRI)
    • Researcher Area
    • Annual Reports ibs.GRANADA
    • Webmail access
    • Transparency
    • Collaborators
  • Research
    • Own Plan ibs.GRANADA
    • Research Areas
    • Research groups
    • Clinical research
    • Collaboration network between groups of the ibs.GRANADA
    • Researcher Finder
    • Publications Search
  • Innovation
    • Innovation
    • Technology Offers
    • Clinical practice guidelines
  • International
    • International Projects Unit
    • International Projects
    • International Networks
  • Training
    • Training
    • Research Sessions
    • PhD Programs
    • Official University Master's Degrees
  • News
    • Calls for applications
    • News
    • Events
  • Job vacancies
    • Job vacancies
    • Human Resources Strategy for Researchers of the European Commission (HRS4R)
  • Platforms

A08-Immune Response and Cancer

Oncology / IBS-A08

ibs.GRANADA  ·  Research groups
  • Information
  • Members
  • Publications
  • Projects
  • Clinical trials

The group is involved in the analysis of the immune response in cancer, the role of infiltrating leukocytes, and the immunophenotypic characteristics of tumor cells. The research group has identified the main escape mechanisms used by tumors (kidney, bladder, prostate and colon cancer) to elude the immune response. In particular, it has focused on those mechanisms that prevent antigen recognition by immune cytotoxic effectors. The most relevant aspects of these defects have been evaluated in various immunotherapy protocols and the possible correction through gene therapy procedures. The group collaborates with various European and American centers that work on the design of cancer vaccines.

Keywords

Cancer Immune Escape, Immunotherapy, Gene Therapy

HERNANI GIL JULIO

JOSE RAMON VILCHEZ GUTIERREZ

ANA BELEN RODRIGUEZ MARTIN

VERONICA SANZ SERRANO

IRENE DIAZ ALVEROLA

MARIA JOSE OLIVARES DURAN

ANTONIO RODRIGUEZ NICOLAS

  • ORCID

TERESA RODRIGUEZ RUIZ

  • ORCID

JOSE MARIA ROMERO NOGUERA

FRANCISCO RUIZ-CABELLO OSUNA

  • ORCID

FERNANDO VAZQUEZ ALONSO

  • ORCID

FRANCISCO JAVIER VICENTE PRADOS

NATALIA APTSIAURI

  • ORCID

MONICA BERNAL SANCHEZ

JOSE MANUEL COZAR OLMO

ANGEL MIGUEL GARCIA LORA

  • ORCID

JUAN FRANCISCO GUTIERREZ BAUTISTA

PILAR JIMENEZ GAMIZ

FRANCISCO JAVIER PEREA GARCIA

  • ORCID

PER ANDERSON

  • ORCID
Munoz-Herrera, CM; Gutierrez-Bautista, JF; Lopez-Nevot, MA

Clinical Case: Patient with Mixed Graft Rejection Four Days after Kidney Transplantation Developed Specific Antibodies against Donor Bw4 Specificities

ANTIBODIES, 2021;

Garzón, I; Jaimes-Parra, BD; Pascual-Geler, M; Cozar, JM; Sanchez-Quevedo, MD; Mosquera-Pacheco, MA; Sanchez-Montesinos, I; Fernandez-Valades, R; Fields, F; Alaminos, M

Biofabrication of a Tubular Model of Human Urothelial Mucosa Using Human Wharton Jelly Mesenchymal Stromal Cells

POLYMERS, 2021;

FI: 4,329; Q1

Garrido, MA; Perea, F; Vilchez, JR; Rodriguez, T.; Anderson, P; Garrido, F.; Ruiz-Cabello, F; Aptsiauri, N.

Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of HLA Class I Alterations in Cancer

CANCER, 2021;

FI: 6,639; Q1

Simon, I; Perales, S; Casado-Medina, L; Rodriguez-Martinez, A; Garrido-Navas, MD; Puche-Sanz, I; Diaz-Mochon, JJ; Alaminos, C; Lupianez, P; Lorente, JA; Serrano, M. J.; Royal, P.J.

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation

CANCER, 2021;

FI: 6,639; Q1

Olmo, JMC; Rodriguez, JC; Rubio-Briones, J; Rodriguez, USA; del Toro, JM; Garcia-Porrero, AG; Juarez-Soto, A.

Clinical drivers for imaging testing in non-metastatic castration-resistant prostate cancer in clinical practice: Results of the IDENTIFICA study

SPANISH UROLOGICAL RECORDS, 2021;

FI: 0,994; Q4

Martinez-Gonzalez, LJ; Antunez-Rodriguez, A; Vazquez-Alonso, F; Hernandez, AF; Alvarez-Cubero, M.J.

Genetic variants in xenobiotic detoxy fication enzymes, antioxidant defenses and hormonal pathways as biomarkers of susceptibility to prostate cancer

SCIENCE OF THE TOTAL ENVIRONMENT, 2020;

FI: 6,551; D1

Cano-Ibanez, N; Barrios-Rodriguez, R; Lozano-Lorca, M; Vazquez-Alonso, F; Arrabal-Martin, M; Trivino-Juarez, JM; Salcedo-Bellido, I; Jimenez-Moleon, JJ; Olmedo-Requena, R.

Dietary Diversity and Prostate Cancer in a Spanish Adult Population: CAPLIFE Study

NUTRIENTS, 2020;

FI: 4,546; Q1

Carrillo-Galvez, AB; Galvez-Peisl, S; Gonzalez-Correa, JE; from Haro-Carrillo, M; Ayllon, V; Carmona-Saez, P; Ramos-Mejia, V; Galindo-Moreno, P; Face, FE; Granados-Principal, S; Munoz, P; Martin, F; Anderson, P

GARP is a key molecule for mesenchymal stromal cell responses to TGF-beta and fundamental to control mitochondrial ROS levels

STEM CELLS TRANSLATIONAL MEDICINE, 2020;

FI: 6,429; Q1

Carrillo-Galvez, AB; Quintero, J.E.; Rodriguez, R; Menendez, ST; Gonzalez, M.V.; Blanco-Lorenzo, V; Allonca, E; Farias, V.D.; Gonzalez-Correa, J.E.; Erill-Sagales, N; Martinez-Zubiaurre, I; Hellevik, T; Sanchez-Hernandez, S; Munoz, P; Zurita, F; Martin, F; Rodrig

GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-beta

CELL DEATH & DISEASE, 2020;

FI: 6,304; Q1

Bolivar-Galiano, F; Abad-Ruiz, C; Sanchez-Castillo, P; Tuscan, M; Romero-Noguera, J.

Frequent Microalgae in the Fountains of the Alhambra and Generalife: Identification and Creation of a Culture Collection.

APPLIED SCIENCES-BASEL, 2020;

FI: 2,474; Q2

Cozar, JM; Robles-Fernandez, I; Rodriguez-Martinez, A; Puche-Sanz, I; Vazquez-Alonso, F; Lorente, J.A.; Martinez-Gonzalez, LJ; Alvarez-Cubero, M.J.

The role of miRNAs as biomarkers in prostate cancer

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2019;

FI: 6,081; D1

Flores-Martin, JF; Perea, F; Exposito-Ruiz, M; Carter, FJ; Rodriguez, T; Villamediana, M; Ruiz-Cabello, F; Garrido, F; Cozar-Olmo, JM; Aptsiauri, N.

A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer

ANNALS OF SURGICAL ONCOLOGY, 2019;

FI: 3,681; Q1

Moron, R; Galvez, J; Colmenero, M; Anderson, P; Head, J; Rodriguez-Cabezas, ME

The Importance of the Microbiome in Critically Ill Patients: Role of Nutrition

NUTRIENTS, 2019;

FI: 4,171; Q1

Garrido, F.

MHC Class-I Loss and Cancer Immune Escape Introduction

MHC CLASS-I LOSS AND CANCER IMMUNE ESCAPE, 2019;

FI: 2,126; Q2

Garrido, F.

MHC / HLA Class I Loss in Cancer Cells

MHC CLASS-I LOSS AND CANCER IMMUNE ESCAPE, 2019;

FI: 2,126; Q2

Aptsiauri, N; Ruiz-Cabello, F; Garrido, F.

The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses

CURRENT OPINION IN IMMUNOLOGY, 2018;

FI: 7,932; D1

Cozar, JM; Robles-Fernandez, I; Martinez-Gonzalez, LJ; Pascual-Geler, M; Rodriguez-Martinez, A; Serrano, MJ; Lorente, J.A.; Alvarez-Cubero, M.J.

Genetic markers a landscape in prostate cancer

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2018;

FI: 5,205; D1

Romero, I; Garrido, C; Algarra, I; Chamorro, V; Collado, A; Garrido, F.; Garcia-Lora, AM

Intratumoral MHC Heterogeneity May Predict Cancer Progression and Response to Immunotherapy

FRONTIERS IN IMMUNOLOGY, 2018;

FI: 5,511; Q1

Pascual-Geler, M; Urquiza-Salvat, N; Cozar, JM; Robles-Fernandez, I; Rivas, A; Martinez-Gonzalez, LJ; Ocana-Peinado, FM; Lorente, J.A.; Alvarez-Cubero, M.J.

The influence of nutritional factors on prostate cancer incidence and aggressiveness

AGING MALE, 2018;

FI: 2,5; Q2

Garrido, MA; Rodriguez, T; Zinchenko, S; Maleno, I; Ruiz-Cabello, F; Shell, A; Olea, N; Garrido, F; Aptsiauri, N.

HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15

IMMUNOGENETICS, 2018;

FI: 2,094; Q3

Arrabal-Polo, MA; Arrabal-Martin, M; Mijan-Ortiz, JL; Vazquez-Alonso, F; Cozar-Olmo, J.M.

Assessing robot-assisted laparoscopic prostatectomy

LANCET, 2017;

FI: 47,831; D1

Morote, J; Innkeeper, AJ; Ossorio, JLA; Ciria, JP; Dominguez-Escrig, JL; Vazquez, F; Angle, J; Lopez, FJ; de La Iglesia, R; Romero, J

Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017;

FI: 5,133; D1

Garrido, F; Ruiz-Cabello, F; Aptsiauri, N.

Rejection versus escape: the MHC tumor dilemma

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017;

FI: 4,711; Q1

Perea, F; Bernal, M; Sanchez-Palencia, A; Carter, J; Towers, C; Bayarri, C; Gomez-Morales, M; Garrido, F; Ruiz-Cabello, F.

The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.

INTERNATIONAL JOURNAL OF CANCER, 2017;

FI: 6,513; Q1

Robles-Fernandez, I; Martinez-Gonzalez, LJ; Pascual-Geler, M; Cozar, JM; Puche-Sanz, I; Serrano, MJ; Lorente, J.A.; Alvarez-Cubero, M.J.

Association between polymorphisms in sex hormone synthesis and metabolism and prostate cancer aggressiveness

PLOSONE, 2017;

FI: 2,806; Q1

Valderrama-Illana, P; Abad-Minor, F; Puche-Sanz, I; Pareja-Vilchez, M; Cozar-Olmo, J.M.

Penile Strangulation Caused by a Seal Ring

ARCHIVES OF SEXUAL BEHAVIOR, 2016;

FI: 2,704; D1

Garrido, F; Aptsiauri, N; Doorduijn, E.M.; Lora, AMG; Van Hall, T.

The urgent need to recover MHC class I in cancers for effective immunotherapy

CURRENT OPINION IN IMMUNOLOGY, 2016;

FI: 7,126; D1

Carter, FJ; del Campo, AB; Flores-Martin, JF; Mendez, R; Garcia-Lopez, C; Cozar, JM; Adams, V; Ward, S; Cabrera, T; Ruiz-Cabello, F; Garrido, F; Aptsiauri, N.

Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016;

FI: 4,846; Q1

Aptsiauri, N; Jewett, A; Hurwitz, AA; Shurin, M.R.; Umansky, V.

Redefining cancer immunotherapy-optimization, personalization, and new predictive biomarkers: 4th Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, April 27-30, 2015, Ljubljana, Slovenia

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016;

FI: 4,846; Q1

Garrido, F.; Romero, I; Aptsiauri, N; Garcia-Lora, AM

Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype

INTERNATIONAL JOURNAL OF CANCER, 2016;

FI: 5,531; Q1

Martin-Martin, L; Lopez, A; Vidriales, B; Caballero, MD; Rodrigues, AS; Ferreira, SI; Lima, M; Almeida, S; Valverde, B; Martinez, P; Ferrer, A; Candeias, J; Ruiz-Cabello, F; Buadesa, JM; Sempere, A; Villamor, N; Orphao, A; Almeida, J

Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile.

ONCOTARGET, 2015;

FI: 6,359; D1

Ortega, FG; Fernandez-Baldo, MA; Serrano, MJ; Messina, GA; Lorente, J.A.; Raba, J.

Epithelial cancer biomarker EpCAM determination in peripheral blood samples using a microfluidic immunosensor based on silver nanoparticles as platform

B-CHEMICAL SENSORS AND ACTUATORS, 2015;

FI: 4,097; D1

Ulzurrun E; Stephens C; Ruiz-Hair F; Robles-Diaz M; Saenz-Lopez P; Hallal H; Soriano G; Roman E; Fernandez MC; Lucena MI; Andrade RJ.

Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort

PLOSONE, 2015;

FI: 3,234; Q1

Alvarez-Cubero, MJ; Martinez-Gonzalez, LJ; Saiz, M; Carmona-Saez, P; Alvarez, JC; Pascual-Geler, M; Lorente, J.A.; Cozar, JM

Prognostic role of genetic biomarkers in clinical progression of prostate cancer

EXPERIMENTAL AND MOLECULAR MEDICINE, 2015;

FI: 3,446; Q2

Matas-Cobos, AM; Round-Cherry, E; Alegria-Motte, C; Martinez-Chamorro, A; Saenz-Lopez, P; Jimenez, P; Jimenez, MRC; Gonzalez-Calvin, JL; de Teresa, J; Osuna, FRC

The Role of Toll-Like Receptor Polymorphisms in Acute Pancreatitis Occurrence and Severity

PANCREAS, 2015;

FI: 2,959; Q2

Latency in the metastatic process as a new strategy to destroy cancer cells

Funder: INSTITUTO DE SALUD CARLOS III

File number: PI15 / 00528

Execution time: 01/01/2016 - 31/12/2018

PI: ANGEL MIGUEL GARCIA LORA

Alteration of antigenic presentation in tumor cells: Involved in immunosurveillance and immunotherapy.

Funder: INSTITUTO DE SALUD CARLOS III

File number: PI17 / 00197

Execution time: 01/01/2018 - 31/12/2020

PI18 / 00826 - MHC class I and immunoescape in colorectal cancer: Evaluation of the diagnostic value of exosomes / cfDNA and study of the role of the tumor stroma

Funder: INSTITUTO DE SALUD CARLOS III

File number: PI18 / 00826

Execution time: 01/02/2019 - 31/12/2021

IP: PER ANDERSON

Deciphering how the immune system controls cancer cells

Funder: INSTITUTO DE SALUD CARLOS III

File number: PI19 / 01179

Execution time: 01/01/2020 - 31/12/2022

PI: ANGEL MIGUEL GARCIA LORA

Observational study of darolutamide in patients with non-metastatic castration-resistant prostate cancer. DAROL

Financer: BAYER HISPANIA SL

Type of test: OBSERVATIONAL STUDY WITH PROSPECTIVE FOLLOW-UP MEDICATIONS

Execution time: 03/12/2021 - 30/09/2026

PI: FERNANDO VAZQUEZ ALONSO

Observational study on the management in clinical practice of castration-resistant prostate cancer with unknown metastatic status (APHRODITE)

Funder: JANSSEN-CILAG, SA

Type of test: COMMERCIAL POST AUTHORIZATION STUDY

Execution time: 23/12/2019 - 30/04/2021

PI: FERNANDO VAZQUEZ ALONSO

facebook icon twitter icon LinkedIn icon whatsapp icon

Responsible researcher

FRANCISCO RUIZ-CABELLO OSUNA

  • francisco.ruizcabello.sspa@juntadeandalucia.es
  • ORCID

Responsible Co-Investigator

JOSE MANUEL COZAR OLMO

  • cozarjm@yahoo.es

Research

  • Collaboration network between groups of the ibs.GRANADA
  • Oncology Area
  • Epidemiology and Public Health Area
  • Precision Medicine Area
  • Advanced Therapies and Biomedical Technologies Area
  • Clinical research

Post navigation

A06-Clinical Oncology and Liquid Biopsy
A09-Genetics and Molecular Oncology

ibs.Granada logo

  • info@ibsgranada.es
  • Avda. De Madrid, 15
    External Consultation Pavilion, 2nd Floor (Old Management Area)
    18012 Grenada.
  • facebook icon
  • twitter icon
  • instagram icon
  • linkedin icon
  • youtube icon
University of Granada
Items isciii
Investigate +
© 2023 ibs.GRENADA
  • Legal Advice
  • Cookies Policy
  • Privacy Policy
  • Contact
  • Site map

We use cookies to offer you the best experience on our website.

You can learn more about which cookies we use or deactivate them in the adjustments.

X
ibs logo.GRANADA
Powered by  GDPR Cookie Compliance
Privacy summary

This website uses cookies so that we can offer you the best possible user experience. The information of the cookies is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.

Technical and necessary cookies

The strictly necessary cookies must always be activated so that we can save your cookie settings preferences.

If you deactivate this cookie we will not be able to save your preferences. This means that every time you visit this website you will have to activate or deactivate cookies again.

Analytics and optimization

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, or the most popular pages.

Leaving this cookie active allows us to improve our website.

Please activate the strictly necessary cookies first so that we can save your preferences!

Cookies policy

More information about our Cookies policy